Ignite Creation Date:
2025-12-24 @ 10:59 PM
Ignite Modification Date:
2026-03-11 @ 7:36 AM
Study NCT ID:
NCT02195869
Status:
COMPLETED
Last Update Posted:
2019-07-11
First Post:
2014-07-11
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Sponsor:
Pharmacyclics LLC.
Organization:
Study Overview
Official Title:
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: